Sitagliptin (trade names: Januvia and Xelevia) is approved for certain adults with type 2 diabetes mellitus whose blood-glucose levels are inadequately controlled by diet and exercise alone. The fixed ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- New data were presented at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions from a study comparing ...
Insulin is needed less frequently and HbA1c is lowered more robustly when adults with type 2 diabetes do not delay combination therapy but begin treatment by taking sitagliptin and metformin together, ...
The study assessed the safety and efficacy of adding JANUVIA (sitagliptin) 100 mg once-daily or dapagliflozin 10 mg once-daily to treatment of patients with mild renal impairment (eGFR ≥60 and <90 ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved JANUMET ® XR ...
Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are not adequately controlled on metformin or sitagliptin alone or in patients already being treated with ...
Results of the study demonstrated that therapy with ONGLYZA 5 mg was non-inferior to JANUVIA 100 mg when added to metformin (difference in adjusted mean change from baseline vs. JANUVIA plus metformin ...
WHITEHOUSE STATION, N.J. Data from five studies presented at the 44th Annual Meeting of the European Association for the Study of Diabetes showed that a combination of Merck’s drug Januvia and ...
Sitagliptin is prescribed metformin januvia 50mg people who still have high blood sugar, even though they have a sensible diet and exercise regularly. It comes as tablets that you swallow. Common side ...
With the addition of these two products, Sandoz continues to support diabetic patients and strengthens its leadership position among generic companies in the diabetes therapeutic class products.
With the two active components, sitagliptin and metformin, Janumet has a comprehensive mechanism of action that targets all three key defects of T2DM for improved glycemic control: diminished insulin ...
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505 (b) (2) route. The Zituvio range of products contain active ingredients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results